Raphael e Marcela convidam novamente Nathalie Santana para falar sobre tratamento do hipertiroidismo em 4 clinicagens: como escolher o melhor tratamento? como controlar os sintomas? como prescrever drogas antitireoidianas? como monitorar o paciente?

Use o cupom TDC2024 para assinar o HITT do Medcof e ganhe um cupom de 6 meses gratuitos do Guia TdC!

https://hiit.grupomedcof.com.br

Referências:

1. Azizi, F et al. “Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.” European journal of endocrinology vol. 152,5 (2005): 695-701. doi:10.1530/eje.1.01904

2. Villagelin, Danilo et al. “Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment.” Thyroid : official journal of the American Thyroid Association vol. 25,12 (2015): 1282-90. doi:10.1089/thy.2015.0195

3. Kahaly, George J et al. “2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.” European thyroid journal vol. 7,4 (2018): 167-186. doi:10.1159/000490384

4. Villagelin, Danilo et al. “A 2023 International Survey of Clinical Practice Patterns in the Management of Graves' Disease: A Decade of Change.” The Journal of clinical endocrinology and metabolism, dgae222. 5 Apr. 2024, doi:10.1210/clinem/dgae222

5. Ross, Douglas S et al. “2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.” Thyroid : official journal of the American Thyroid Association vol. 26,10 (2016): 1343-1421. doi:10.1089/thy.2016.0229

6. Shalaby M, Hadedeya D, Toraih EA, et al. Predictive factors of radioiodine therapy failure in Graves' Disease: A meta-analysis. Am J Surg. 2022;223(2):287-296. doi:10.1016/j.amjsurg.2021.03.068

7. Carella, C et al. “Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.” Thyroid : official journal of the American Thyroid Association vol. 16,3 (2006): 295-302. doi:10.1089/thy.2006.16.295 8. Struja T, Kaeslin M, Boesiger F, et al. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176(4):413-419. doi:10.1530/EJE-16-0986

9. Park SY, Kim BH, Kim M, et al. The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea. Endocrine. 2021;74(1):120-127. doi:10.1007/s12020-021-02725-x

10. Azizi F, Amouzegar A, Tohidi M, et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Thyroid. 2019;29(9):1192-1200. doi:10.1089/thy.2019.0180

11. Chaker L, Cooper DS, Walsh JP, Peeters RP. Hyperthyroidism. Lancet. 2024;403(10428):768-780. doi:10.1016/S0140-6736(23)02016-0

12. Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472-1483. doi:10.1001/jama.2023.19052

13. https://www.tadeclinicagem.com.br/guia/146/tempestade-tireotoxica/

Fred Amorim e Ingrid Froehner convidam Gabriel Cunha para falar sobre eletroforese de proteínas e outros exames na investigação de gamopatia monoclonal (imunofixação e cadeias livres e leves).

Referências em breve.

Rapha, Luísa e Lucas conversam sobre a primeira consulta de um paciente com doença renal crônica baseado no novo KDIGO 2024!

Como estadiar? É um quadro agudo ou crônico? O que está causando? Como estimar riscos? Quais são as primeiras condutas terapêuticas? Tudo isso aqui!

Minutagem:

(03:36) Definição e diagnóstico

(20:14): Etiologia

(26:16) Estadiamento

(33:56) Estratificação de risco renal e cardiovascular

(42:13) Primeiras condutas terapêuticas

Referências:

1. STEVENS, Paul E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international, v. 105, n. 4, p. S117-S314, 2024.

2. PERKOVIC, Vlado et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 2024.

3. https://www.tadeclinicagem.com.br/guia/100/atualizacao-kdigo-2022-de-manejo-de-diabetes-na-doenca-renal-cronica/

4. https://www.tadeclinicagem.com.br/guia/272/bicarbonato-na-doenca-renal-cronica/

5. https://www.tadeclinicagem.com.br/guia/31/gliflozinas-inibidores-da-sglt2/

6. https://www.tadeclinicagem.com.br/guia/253/finerenona-na-nefropatia-diabetica/

7. https://www.tadeclinicagem.com.br/guia/edition/edicao-86/#analogos-de-glp-1-para-doenca-renal-cronica